including focused amino acid substitutions or additions to increase molecular interactions with synthetic phospholipids and phosphonolipids

ts were re-suspended in 0.5 ml homogenization buffer. Protein concentration was determined using the bicinchoninic acid protocol. The chymotrypsin-like and trypsin-like activities of purified proteasomes from infected and uninfected cells were tested using the fluorogenic GLPG0634 chemical information substrates SucLLVY-AMC and Boc-LRR-AMC, respectively, in the presence or absence of the proteasome inhibitor 25 mM carbobenzoxy-Lleucyl-L-leucyl-L-leucinal, as previously described. Fluorescence was determined using a fluorimeter, and proteasome activity was expressed as arbitrary fluorescence units. The two-tailed Wilcoxon signed-rank test was used for statistical analysis of the results. Vaccination against Herpes Simplex Virus in a similar fashion, both in vitro and in vivo, with comparable attenuation. Analysis of protection against lethal infection with wildtype HSV1 after immunization of mice with live attenuated recombinant HSV1 vectors To investigate the potential use of the two attenuated HSV1 vectors as anti-HSV vaccines, groups of female BALB/c and C57BL/6 mice were given a single intravaginal immunization of either HSV1-Tat or HSV1-LacZ at 103 pfu/mouse. Control mice received PBS alone. At day 28, all mice were challenged intravaginally with a lethal dose of wild-type HSV1, and monitored for signs of disease and survival. As shown in Analysis of protection against a lethal challenge with wild-type HSV1 in mice immunized with live attenuated recombinant HSV1-LacZ vector and Tat protein To confirm the protective role of Tat, C57BL/6 mice were immunized intravaginally with 103 pfu/mouse of the HSV1-LacZ vector, with or without 5 mg of biologically active Tat protein, given intradermally. At day 28, all mice were challenged intravaginally with the lethal dose of wild-type HSV1 and monitored for survival and the appearance of signs of the disease. As shown in including the immunodominant SSIEFARL and ITAYGLVL epitopes, respectively derived from HSV1 glycoprotein B and glycoprotein K, and the subdominant QTFDFGRL epitope derived from ribonucleotide reductase 1. Similarly, T-cell responses in BALB/c mice were 16177223 evaluated 16041400 using two peptides, including the peptide SLKMADPNRFRGKDLP, which contains both the Hbrestricted CD4 and Kd-restricted CD8 immunodominant epitopes derived from glycoprotein D, and the CTL subdominant epitope DYATLGVGV, derived from ICP27. As shown in Analysis of HSV1-specific humoral response in mice immunized with recombinant HSV1 vectors Analysis of HSV1-specific T-cell responses in mice infected with recombinant HSV1 vectors To determine the effect of Tat expression on the induction of HSV1-specific T-cell mediated responses, female C57BL/6 and BALB/c mice were infected intravaginally with 103 pfu/mouse of the attenuated replication-competent recombinant HSV1-LacZ or HSV1-Tat viruses. After 7 days, the presence of HSV1-specific Tcell responses in C57BL/6 mice was evaluated by IFN-c and IL-4 ELISpot assays on fresh splenocytes. T-cell responses were evaluated using three Kb-restricted CTL peptide epitopes, Vaccination against Herpes Simplex Virus vectors. These results demonstrate that intravaginal immunization of two different strains of mice with a recombinant HSV1 vector expressing Tat can promote the induction of HSV1-specific antibody responses, while immunization with a recombinant HSV1-LacZ vector cannot. Effect of recombinant HSV1 vectors on proteasome activities As the vast majority of CTL epitopes are generated by proteasomes, the effect